The physiological impact of an N-terminal Halo-tag on glucose-dependent insulinotropic polypeptide receptor function in mice. [PDF]
Davies I +6 more
europepmc +1 more source
Prescribing Trajectories in Type 2 Diabetes in the United States, 2019–2024
ABSTRACT Importance Clinical guidelines for type 2 diabetes (T2D) provide population‐level recommendations, but real‐world treatment patterns evolve dynamically and vary across patients. Understanding longitudinal prescribing trajectories may reveal heterogeneity in care not captured by cross‐sectional analyses.
Tobias S. Lux +14 more
wiley +1 more source
Comparison of Perioperative Glycemic Control in Patients Continuing Versus Temporarily Holding Glucagon-Like Peptide-1 Receptor Agonists or Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists Preoperatively. [PDF]
Trykall CC +6 more
europepmc +1 more source
ABSTRACT Aims Treatment options for metabolic dysfunction‐associated steatotic liver disease (MASLD) are limited. While glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) and sodium‐glucose cotransporter‐2 (SGLT‐2) inhibitors improve cardiovascular outcomes, comparative effectiveness on liver‐related outcomes remains unclear.
Gregor A. Maier +4 more
wiley +1 more source
Downstream interaction by glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide agonism is required for synergistic effects on body weight. [PDF]
Feetham CH +9 more
europepmc +1 more source
ABSTRACT Aims To evaluate the effect of tirzepatide on body weight, glycaemic control, insulin requirements, continuous glucose monitoring (CGM) metrics and cardiorenal parameters in adults with Type 1 diabetes (T1D) and overweight or obesity. Materials and Methods In this retrospective matched cohort study, adults with T1D, BMI ≥ 27 kg/m2, CGM use and
Amanda R. Purcell +3 more
wiley +1 more source
MAFLD/MASLD: Past, Present, and Future
ABSTRACT Metabolic dysfunction‐associated steatotic liver disease (MASLD), also known as nonalcoholic fatty liver disease and metabolic dysfunction‐associated fatty liver disease, affects more than 30% of the global adult population and has become one of the leading causes of cirrhosis and hepatocellular carcinoma.
Vincent Wai‐Sun Wong
wiley +1 more source
Novel Use of Glucagon-Like Peptide-1 (GLP-1) and Dual Glucose-Dependent Insulinotropic Polypeptide (GIP)/GLP-1 Receptor Agonists in Maturity-Onset Diabetes of the Young (MODY). [PDF]
Hilal A, Afandi B, Almazrouei R.
europepmc +1 more source
Molecular mechanisms underlying glucose-dependent insulinotropic polypeptide secretion in human duodenal organoids. [PDF]
Guccio N +9 more
europepmc +1 more source
The interplay of glucose-dependent insulinotropic polypeptide in adipose tissue. [PDF]
Kagdi S, Lyons SA, Beaudry JL.
europepmc +1 more source

